FDA warns Boston Sci over stent-graft system problems

  • Updated: September 7, 2007 - 8:28 PM

Boston Scientific Corp. received a warning letter from U.S. regulators concerning safety violations, including failing to promptly report the deaths of five patients enrolled in clinical trials of a device used to treat ruptured blood vessels in the abdomen.

  • 0
  • Comments

There are currently no comments for this article

Comment on this story   |   Be the first to comment

Be the first to comment

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT